Aldeyra Therapeutics Inc (STU:137)
€ 5.158 0.084 (1.66%) Market Cap: 303.87 Mil Enterprise Value: 206.88 Mil PE Ratio: 0 PB Ratio: 3.34 GF Score: 40/100

Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 Call Transcript

Jun 29, 2023 / 12:00PM GMT
Release Date Price: €7.4 (+9.47%)
Operator

Hello, and welcome to the Aldeyra Therapeutics provides top line results from Phase II clinical trial of ADX-2191 in patients with retinitis pigmentosa call. (Operator Instructions) I will now turn the conference over to David Burke, Head of Investor Relations. Please go ahead.

David Burke
Aldeyra Therapeutics, Inc. - Head of IR

Thank you, and good morning, everyone. With me today is Dr. Todd Brady, President and Chief Executive Officer of Aldeyra. This morning, we issued a press release reporting top line results for the Phase II clinical trial of ADX-2191 in retinitis pigmentosa. A copy of the press release is available on the Investor and Media section of our website, www.aldeyra.com.

The press release contains important information and should be read and considered in conjunction with the slides presented in the prepared remarks made on today's call. Turning to Slide 2. This presentation and various remarks, which may be made during this presentation contain forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot